Enjoy complimentary customisation on priority with our Enterprise License!
The epilepsy therapeutic market in APAC share is expected to increase by USD 296.44 million from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 4.01%.
This epilepsy therapeutic market in the APAC research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers the epilepsy therapeutics market in APAC segmentations by product (first-generation epilepsy therapeutic, second-generation epilepsy therapeutic, and third-generation epilepsy therapeutic) and geography (Asia and the Rest of APAC). The epilepsy therapeutics market in the APAC report also offers information on several market vendors, including Bausch Health Companies Inc., BIAL - PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., SanofiSA, Sunovion Pharmaceuticals Inc., UCB SA, and Zogenix Inc. among others.
Download Report Sample to Unlock the Epilepsy therapeutics Market in APAC Size for the Forecast Period and Other Important Statistics
The increase in the patient population is notably driving the epilepsy therapeutics market in APAC growth, although factors such as generic erosion may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the epilepsy therapeutics market in the APAC. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Epilepsy Therapeutics Market In APAC Driver
An increase in the patient population is one of the major drivers of the epilepsy therapeutics market growth in the APAC. The annual incidence rate of epilepsy in developed countries is approximately 45-55 per 100,000 individuals, with higher rates in infants and older populations. In developing countries, the incidence rate is almost double, reaching about 95-105 per 100,000 individuals annually. The prevalence rate of epilepsy in developed countries is estimated between 5-10 per 1,000 individuals annually, whereas this rate is much higher in developing countries, reaching approximately 125-135 individuals annually. The developing countries witness high incidence and prevalence rates due to the increasing population, and the lack of proper diagnostic tools refraining from detecting the early symptoms of epilepsy. The increase in the patient population is expected to increase the consumption of AEDs, thereby driving market growth.
Key Epilepsy Therapeutics Market In APAC Trend
The emergence of new-generation AEDs is one of the major trends in the epilepsy therapeutics market growth in the APAC. The epilepsy therapeutics market in APAC is currently witnessing a shift in focus toward second-generation AEDs. These drugs offer various advantages over first-generation AEDs such as simpler pharmacokinetic profiles. Japan is anticipated to experience a major shift in the trend toward second-generation drugs because of the recent launch of these drugs in the Japanese market. However, various territories in the APAC region are still dominated by first-generation AEDs. Market stratification of major vendors to penetrate the countries in APAC and increasing healthcare reforms are expected to change the epilepsy treatment regimen. Third-generation AEDs such as VIMPAT (lacosamide) is also fueling the growth of the market.
Key Epilepsy Therapeutics Market In APAC Challenge
Generic erosion is one of the major challenges to the epilepsy therapeutics market growth in the APAC. Patent expiry of a drug often results in the loss of an exclusive market for that drug, leading to a rapid decline in sales. For instance, LYRICA lost its exclusivity in 2019. As a result, the revenue of LYRICA in Canada and the EU decreased significantly. Similarly, the loss of exclusivity in APAC is anticipated to negatively impact the epilepsy therapeutics market in APAC. Since April 2009, Pfizer has filed lawsuits in the US District Court for the District of Delaware against generic manufacturers who have filed Abbreviated New Drug Applications (ANDAs) for LYRICA. Therefore, generic manufacturers for LYRICA could not obtain US FDA approval until LYRICA's basic patent expired in 2018. The regulatory exclusivity for LYRICA was valid until 2014 in the EU. In July 2013, UCB filed lawsuits against generic manufacturers such as Mylan, Sun Pharma, Ranbaxy, and Aurobindo Pharma for overfilling of ANDA for VIMPAT. Once these generics are launched in developed countries, they reach APAC within 6-9 months from their launch. Such instances are anticipated to negatively impact the market in APAC during the forecast period.
This epilepsy therapeutics market in the APAC analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Technavio categorizes the epilepsy market in APAC 2021-2025 as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the epilepsy therapeutics market in APAC during the forecast period.
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
This statistical study of the epilepsy therapeutics market in APAC encompasses successful business strategies deployed by the key vendors. The epilepsy therapeutics market in APAC is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The epilepsy therapeutics market in the APAC forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the epilepsy therapeutics market in APAC, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
The report has further elucidated other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
For more insights on the market share of various regions Request PDF Sample now!
76% of the market’s growth will originate from Asia during the forecast period. Japan, China, India, Australia, and South Korea (Republic of Korea) are the key markets for the epilepsy therapeutics market in APAC in Asia. Market growth in this region will be faster than the growth of the market in regions.
The rise in the incidence rate of epilepsy will facilitate the epilepsy therapeutics market growth in Asia over the forecast period. To garner further competitive intelligence and regional opportunities in store for vendors, view our sample report.
To gain further insights on the market contribution of various segments Request PDF Sample
The epilepsy therapeutics market share growth in APAC by the first-generation epilepsy therapeutics segment will be significant during the forecast period. The first-generation AEDs include benzodiazepines, carbamazepine, phenytoin, valproic acid, and phenobarbital. These drugs usually require close monitoring and often lead to life-threatening reactions.
This report provides an accurate prediction of the contribution of all the segments to the growth of the epilepsy therapeutics market in APAC size and actionable market insights on post COVID-19 impact on each segment.
|
Epilepsy therapeutics Market In APAC Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.01% |
|
Market growth 2021-2025 |
$ 296.44 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
2.37 |
|
Regional analysis |
Asia and Rest of APAC |
|
Performing market contribution |
Asia at 76% |
|
Key consumer countries |
Japan, China, India, Australia, and South Korea (Republic of Korea) |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Bausch Health Companies Inc., BIAL - PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., SanofiSA, Sunovion Pharmaceuticals Inc., UCB SA, and Zogenix Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Product
6 Customer landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Drivers, Challenges, and Trends
10 Vendor Landscape
11 Vendor Analysis
12 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
